viewImmuPharma PLC

Immupharma PLC - Share Subscription into Incanthera plc

RNS Number : 3634A
Immupharma PLC
29 September 2020


                                                                                                                                                               29 September 2020


ImmuPharma plc


("ImmuPharma" or the "Company")


Share Subscription into Incanthera plc




ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that further to a subscription agreement entered into at the time of Incanthera's IPO onto AQSE Growth Market* in February 2020, ImmuPharma has now executed its subscription agreement to subscribe £250,000 for 2,631,579 ordinary shares of 2p each at a subscription price equal to Incanthera's IPO price of 9.5p each.


Following this subscription, ImmuPharma will hold 9,904,319 shares in Incanthera, representing a 15.35% position in the enlarged share capital of Incanthera.


ImmuPharma notes two recent positive announcements from Incanthera regarding studies of its lead product Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. These announcements can be viewed on Incanthera's website:






Commenting on the announcement, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer said:


"ImmuPharma is a strong supporter of Incanthera, sharing common goals of progressing both of our therapeutic pipelines to benefit the long term health of patients, globally.


We are extremely pleased to note Incanthera's two recent announcements, evidencing great progress towards its immediate goal of taking its lead product Sol to market."


*Formerly known as NEX Exchange Growth Market


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR").


For further information please contact:


ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer


Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496



SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin


Stanford Capital Partners (Joint Broker)

Patrick Claridge

John Howes

Bob Pountney


SI Capital (Joint Broker)

Nick Emerson


+44 (0) 203 368 3550



+44 (0) 203 815 8880



+44 (0) 1483 413500



4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy


Degroof Petercam (Liquidity Provider)

Erik De Clippel


Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60



+32 (0) 2 287 95 34




+32 (0) 477 504 784

+32 (0) 475 903 909





Notes to Editors


About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer.


The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggests therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.


For additional information about ImmuPharma please visit www.immupharma.co.uk.


ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.



About Incanthera plc


Incanthera (AQSE: INC), is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.


The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.


Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.


For more information please visit: www.incanthera.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: ImmuPharma PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3...

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion...

4 days, 3 hours ago

5 min read